SCHEMBL6090436

SCHEMBL6090436

N#Cc1c[nH]c2ccc(Oc3ccc(OCc4ccccc4)cc3)cc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.70
PFKFB2 O60825 1/20 0.56
PFKFB1 P16118 1/20 0.56
PFKFB3 Q16875 1/20 0.56
LTA4H P09960 5/20 0.53
PLA2G2A P14555 5/20 0.53
MAOB P27338 2/20 0.52
TRPM8 Q7Z2W7 3/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
NSD2 O96028 1/20 0.51
AS3MT Q9HBK9 1/20 0.51
HTR1D P28221 3/20 0.49
SLC6A4 P31645 1/20 0.47
KIF20A O95235 1/20 0.47
POLB P06746 1/20 0.47
MEN1 O00255 1/20 0.47
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5857843 0.92 IMPDH2 (0.81) IMPDH2LTA4HPLA2G2AMAOBTRPM8
SCHEMBL6086627 0.87 PFKFB2 (0.59) IMPDH2PFKFB2PFKFB1PFKFB3LTA4H
SCHEMBL27708665 0.82 IMPDH2 (1.00) IMPDH2LTA4HPLA2G2AMAOBTRPM8
SCHEMBL6087313 0.80 PFKFB2 (0.61) IMPDH2PFKFB2PFKFB1PFKFB3TRPM8
SCHEMBL1657036 0.79 MAOB (0.82) IMPDH2MAOBMAPT
SCHEMBL5858420 0.76 AS3MT (0.86) IMPDH2PFKFB2PFKFB1PFKFB3LTA4H
SCHEMBL6087198 0.76 LTA4H (0.55) LTA4HPLA2G2ATRPM8KDM4EMAPT
SCHEMBL1336627 0.76 MAOB (0.62) IMPDH2MAOBKDM4EMAPTNSD2
SCHEMBL273476 0.75 TRPM8 (0.67) IMPDH2LTA4HPLA2G2ATRPM8KDM4E
SCHEMBL187805 0.75 IMPDH2 (0.65) IMPDH2MAOBMAPTSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7125906-B2 Indole derivatives having anti-angiogenetic activity ASTRAZENECA AB (SE) 2006-10-24 US disclosed
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization ASTRAZENECA AB (SE) 2005-07-21 US disclosed
EP-1515716-A2 INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY Astrazeneca AB (SE) 2005-03-23 EP disclosed
WO-2003082271-A2 INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY ASTRAZENECA AB (SE) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization FLT1, FLT4, VEGFA IMPDH2 3719/4885PFKFB2 1285/4885PFKFB1 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.